These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26514939)

  • 21. The role of intra- and extragenic compensatory mutations in the suppression of fluoroquinolone resistance in a Salmonella Typhimurium gyrA mutant (D87G).
    Preisler A; Heisig P
    J Antimicrob Chemother; 2009 Feb; 63(2):290-4. PubMed ID: 19033246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WQ-3810, a fluoroquinolone with difluoropyridine derivative as the R1 group exerts high potency against quinolone-resistant
    Koide K; Kim H; Whelan MVX; Belotindos LP; Tanomsridachchai W; Changkwanyeun R; Usui M; Ó Cróinín T; Thapa J; Nakajima C; Suzuki Y
    Microbiol Spectr; 2024 Aug; ():e0432223. PubMed ID: 39162520
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence and mechanisms of quinolone resistance among selected nontyphoid Salmonella isolated from food animals and humans in Korea.
    Tamang MD; Nam HM; Kim A; Lee HS; Kim TS; Kim MJ; Jang GC; Jung SC; Lim SK
    Foodborne Pathog Dis; 2011 Nov; 8(11):1199-206. PubMed ID: 21877929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
    Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
    J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-targeting properties of the 3-aminopyrrolidyl quinolones, DC-159a and sitafloxacin, against DNA gyrase and topoisomerase IV: contribution to reducing in vitro emergence of quinolone-resistant Streptococcus pneumoniae.
    Okumura R; Hirata T; Onodera Y; Hoshino K; Otani T; Yamamoto T
    J Antimicrob Chemother; 2008 Jul; 62(1):98-104. PubMed ID: 18390884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High prevalence of plasmid-mediated quinolone resistance determinant aac(6')-Ib-cr amongst Salmonella enterica serotype Typhimurium isolates from hospitalised paediatric patients with diarrhoea in China.
    Yu F; Chen Q; Yu X; Pan J; Li Q; Yang L; Chen C; Zhuo C; Li X; Zhang X; Huang J; Wang L
    Int J Antimicrob Agents; 2011 Feb; 37(2):152-5. PubMed ID: 21163630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quinolone resistance-associated amino acid substitutions affect enzymatic activity of Mycobacterium leprae DNA gyrase.
    Yamaguchi T; Yokoyama K; Nakajima C; Suzuki Y
    Biosci Biotechnol Biochem; 2017 Jul; 81(7):1343-1347. PubMed ID: 28417702
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida.
    Caspar Y; Siebert C; Sutera V; Villers C; Aubry A; Mayer C; Maurin M; Renesto P
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural signature of Ser83Leu and Asp87Asn mutations in DNA gyrase from enterotoxigenic Escherichia coli and impact on quinolone resistance.
    Mehla K; Ramana J
    Gene; 2016 Jan; 576(1 Pt 1):28-35. PubMed ID: 26424597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii.
    Gu DX; Hu YJ; Zhou HW; Zhang R; Chen GX
    Microb Drug Resist; 2015 Jun; 21(3):345-51. PubMed ID: 25514581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
    Turner AK; Nair S; Wain J
    J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the mechanism of quinolone resistance in nalidixic acid-resistant clinical isolates of Salmonella serotype Typhimurium.
    Ruiz J; Castro D; Goñi P; Santamaria JA; Borrego JJ; Vila J
    J Med Microbiol; 1997 Jul; 46(7):623-8. PubMed ID: 9236748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of Quinolone Resistance in Salmonella typhimurium Pig Isolates Determined by gyrA Gene Mutation Using PCR- and Sequence-Based Techniques within the gyrA Gene.
    Macías Farrera GP; Borroto ET; Ramírez FR; Vázquez Chagoyán JC; Rojas MT; Angel GY; de Oca Jimenez RM
    Curr Pharm Des; 2016; 22(33):5079-5084. PubMed ID: 27494067
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel gyrB mutation in a fluoroquinolone-resistant clinical isolate of Salmonella typhimurium.
    Gensberg K; Jin YF; Piddock LJ
    FEMS Microbiol Lett; 1995 Oct; 132(1-2):57-60. PubMed ID: 7590165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Presence of plasmid-mediated quinolone resistance determinants and mutations in gyrase and topoisomerase in Salmonella enterica isolates with resistance and reduced susceptibility to ciprofloxacin.
    Casas MR; Camargo CH; Soares FB; da Silveira WD; Fernandes SA
    Diagn Microbiol Infect Dis; 2016 May; 85(1):85-9. PubMed ID: 26971183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance.
    Suzuki Y; Nakajima C; Tamaru A; Kim H; Matsuba T; Saito H
    Int J Antimicrob Agents; 2012 May; 39(5):435-9. PubMed ID: 22421328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
    Korzheva N; Davies TA; Goldschmidt R
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutant prevention concentrations of ciprofloxacin and enrofloxacin for Salmonella enterica.
    Randall LP; Cooles SW; Piddock LJ; Woodward MJ
    J Antimicrob Chemother; 2004 Sep; 54(3):688-91. PubMed ID: 15243029
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
    Deguchi T; Kikuchi M; Yasuda M; Ito S
    J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.